Danaher Corporation $DHR Shares Sold by ABN Amro Investment Solutions

ABN Amro Investment Solutions reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 10.6% during the 1st quarter, HoldingsChannel reports. The fund owned 343,655 shares of the conglomerate’s stock after selling 40,641 shares during the period. Danaher accounts for 0.8% of ABN Amro Investment Solutions’ portfolio, making the stock its 25th largest position. ABN Amro Investment Solutions’ holdings in Danaher were worth $65,157,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of DHR. Norges Bank acquired a new stake in Danaher during the fourth quarter worth about $2,177,106,000. Viking Global Investors LP grew its stake in Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock worth $574,351,000 after buying an additional 2,455,994 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Danaher by 104.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock worth $991,923,000 after acquiring an additional 2,216,789 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Danaher by 11.2% in the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after acquiring an additional 1,517,904 shares during the period. Finally, Capital International Investors boosted its position in Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $179.01 on Wednesday. The firm has a market cap of $126.70 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 2.48 and a beta of 0.79. The stock has a 50 day moving average of $184.22 and a 200-day moving average of $197.69. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.84 by $0.10. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.11 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.77 EPS. As a group, analysts forecast that Danaher Corporation will post 8.45 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s payout ratio is 30.95%.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher posted Q2 adjusted EPS of $1.94, above the $1.84 consensus, and revenue of about $6.26 billion to $6.3 billion, also ahead of estimates. Danaher Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year adjusted EPS guidance, showing confidence in profitability despite the softer sales backdrop. Danaher Corp (DHR) Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Life Sciences was a bright spot, with stronger sales growth, but bioprocessing revenue came in weaker than expected and was cited as a drag on sentiment. Reuters: Danaher’s revenue outlook cut, biotech miss overshadow profit forecast raise
• Negative Sentiment: Investors reacted negatively to the reduced core revenue growth outlook and cautious near-term guidance, which outweighed the earnings beat and led to the stock decline. Danaher stock slips despite Q2 earnings beat, raised guidance
• Negative Sentiment: Analysts also highlighted “surprisingly soft” bioprocessing sales, reinforcing concerns that growth may slow more than expected. Danaher Plummets After One Segment Comes In ‘Surprisingly Soft’

Analyst Upgrades and Downgrades

DHR has been the topic of several research reports. TD Cowen cut their price objective on Danaher from $245.00 to $240.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. HSBC lowered their target price on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Guggenheim cut their target price on Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Royal Bank Of Canada started coverage on Danaher in a research note on Thursday, May 14th. They set an “outperform” rating and a $200.00 target price for the company. Finally, Weiss Ratings raised shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $231.64.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.